Suppr超能文献

使用临床适用的方法从人胚胎干细胞生成 CD34+细胞,并在胎羊模型中进行移植。

Generation of CD34+ cells from human embryonic stem cells using a clinically applicable methodology and engraftment in the fetal sheep model.

机构信息

Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI 53705, USA.

出版信息

Exp Hematol. 2013 Aug;41(8):749-758.e5. doi: 10.1016/j.exphem.2013.04.003. Epub 2013 Apr 20.

Abstract

Until now, ex vivo generation of CD34(+) hematopoietic stem cells (HSCs) from human embryonic stem cells (hESCs) mostly involved use of feeder cells of nonhuman origin. Although they provided invaluable models to study hematopoiesis, in vivo engraftment of hESC-derived HSCs remains a challenging task. In this study, we used a novel coculture system composed of human bone marrow-derived mesenchymal stromal/stem cells (MSCs) and peripheral blood CD14(+) monocyte-derived macrophages to generate CD34(+) cells from hESCs in vitro. Human ESC-derived CD34(+) cells generated using this method expressed surface makers associated with adult human HSCs and upregulated hematopoietic stem cell genes comparable to human bone marrow-derived CD34(+) cells. Finally, transplantation of purified hESC-derived CD34(+) cells into the preimmune fetal sheep, primed with transplantation of MSCs derived from the same hESC line, demonstrated multilineage hematopoietic activity with graft presence up to 16 weeks after transplantation. This in vivo demonstration of engraftment and robust multilineage hematopoietic activity by hESC-derived CD34(+) cells lends credence to the translational value and potential clinical utility of this novel differentiation and transplantation protocol.

摘要

迄今为止,从人胚胎干细胞(hESC)体外生成 CD34(+)造血干细胞(HSCs)大多涉及使用非人类来源的饲养细胞。虽然它们提供了研究造血的宝贵模型,但 hESC 衍生的 HSCs 的体内植入仍然是一项具有挑战性的任务。在这项研究中,我们使用了一种由人骨髓间充质基质/干细胞(MSC)和外周血 CD14(+)单核细胞衍生的巨噬细胞组成的新型共培养系统,从 hESC 体外生成 CD34(+)细胞。使用这种方法生成的 hESC 衍生的 CD34(+)细胞表达与成人人类 HSCs 相关的表面标志物,并上调与人类骨髓衍生的 CD34(+)细胞相当的造血干细胞基因。最后,将纯化的 hESC 衍生的 CD34(+)细胞移植到预先免疫的胎儿绵羊中,该绵羊预先移植了来自同一 hESC 系的 MSC,证明了多谱系造血活性,移植后 16 周仍存在移植物。hESC 衍生的 CD34(+)细胞的这种体内植入和强大的多谱系造血活性证明了这种新型分化和移植方案的转化价值和潜在临床应用。

相似文献

引用本文的文献

本文引用的文献

2
Mesenchymal stromal cells: new directions.间质基质细胞:新方向。
Cell Stem Cell. 2012 Jun 14;10(6):709-716. doi: 10.1016/j.stem.2012.05.015.
5
Hematopoietic stem cell engineering at a crossroads.造血干细胞工程正处于十字路口。
Blood. 2012 Feb 2;119(5):1107-16. doi: 10.1182/blood-2011-09-349993. Epub 2011 Nov 17.
8
MSCs in hematopoietic cell transplantation.造血细胞移植中的间充质干细胞。
Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S21-9. doi: 10.1016/j.bbmt.2010.11.026.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验